ArticleCancer research communications2026
Survival of U.S. Military Service Members with Hodgkin Lymphoma by Post-9/11 Deployment Status.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Classic Hodgkin lymphoma (CHL) commonly affects adolescents and young adults (AYA), including service members (SM). The impact of deployment on CHL outcomes remains unknown. TRICARE beneficiaries diagnosed with CHL from 2001 to 2022 were identified through the Department of War cancer registry. Deployment history came from the Defense Manpower Data Center, and mortality data came from the National Death Index. Mortality was compared between SMs with and without post-9/11 deployment, and associations with deployment-specific variables were evaluated using Cox models adjusted for demographic and clinical factors. An exploratory analysis was performed to assess the survival of AYA SMs by race and to compare mortality with the Surveillance, Epidemiology, and End Results (SEER) database. Among 752 SMs identified, 369 (49%) had deployed after 9/11. Deployment was not associated with overall mortality [adjusted hazard ratio (aHR), 1.64; 95% confidence interval (CI), 0.84-3.19] or disease-specific mortality (aHR, 0.67; 95% CI, 0.13-3.55). No deployment-specific variable meaningfully influenced mortality. There were 21 out of 417 (5%) all-cause deaths in White AYA SMs compared with 0 out of 89 in Black AYA SMs (log-rank test P = 0.0198). Compared with SEER, SMs had lower all-cause mortality (aHR, 0.52; 95% CI, 0.38-0.72) and disease-specific mortality (aHR, 0.29; 95% CI, 0.15-0.59). Post-9/11 deployment did not adversely affect survival among SMs with CHL, highlighting the need for exposure-specific and survivorship-focused research. Survival disparities by race were not appreciated, and mortality in SMs was lower than SEER, highlighting access to care within the Military Health System (MHS) and the healthy soldier effect. SIGNIFICANCE: In this national cohort of 752 U.S. SMs with CHL, post-9/11 deployment and deployment-related variables did not adversely affect overall or disease-specific survival. These findings suggest that deployment exposures or occupational demands do not meaningfully alter CHL outcomes. Lower mortality compared with SEER underscores the healthy soldier effect and highlights the advantages of universal access to timely, coordinated cancer care within the MHS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.